Emerging research on epigenetic alterations (BAP1, PBRM1, SETD2, CDKN2A) and tumor-stroma interactions is identifying new drug targets, including DNA damage response and CDK4/6 inhibitors, as well as microenvironment-directed therapies such as CSF1R blockade [135]. This evidence concerns the gene BAP1 and neoplasm.